Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephanie Cherqui
University of California, San Diego, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
GenStem Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Cherqui is a co-founder of GenStem Therapeutics (GenStem), on the Board of Directors, member of the Scientific Advisory Board and holds (b)(4) equity valued between (b)(4). GenStem's main objective is to bring new stem cell gene therapy to cystinosis patients. This project is conducting the pharmacology/toxicology studies required for inclusion in an IND for a phase I clinical trial for autologous gene-modified-hematopoietic stem cells transplantation for cystinosis.
Lentiviral-transduced hematopoictic stem cell transplantation for cystinosis
Cystinosis is an hereditary disease characterized by the accumulation of cystine in all the cells of the body leading to cell death and tissue damage to kidneys, liver, eyes, muscle and brain. We showed that healthy hematopoietic stem cells (HSCs), which are naturally available in the body, can rescue this disease in the mouse model of cystinosis and we are currently developing a clinical trial that allows the patients' own stem cells to be isolated, corrected for the genetic defect and reintroduced to the body to stimulate healing. We are now proposing strategies to improve this stem cell-gene therapy approach and to investigate which patients' genetic profile will benefit the most from the future clinical trial
Filed on September 12, 2017.
Tell us what you know about Stephanie Cherqui's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stephanie Cherqui filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephanie Cherqui | University of California, San Diego | Conflict of Interest | AVROBIO | $20,000 - $39,999 |
| Stephanie Cherqui | University of California, San Diego | Conflict of Interest | GenStem Therapeutics | $0 - $4,999 |
| Stephanie Cherqui | Scripps Research Institute | Conflict of Interest | GenStem Therapeutics | $0 - $4,999 |
Other search results for: “Stephanie Cherqui”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stephanie Cherqui | University of California, San Diego | Financial Disclosure | Cystinosis Research Foundation |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.